Neurotoxicity Research

, Volume 17, Issue 3, pp 268–278 | Cite as

Genetic Susceptibility in Solvent Induced Neurobehavioral Effects

  • L. Godderis
  • N. Maertens
  • V. de Gelder
  • A. De Lamper
  • K. De Ruyck
  • M. Vernimmen
  • S. Bulterys
  • G. Moens
  • H. Thierens
  • M. K. Viaene
Article

Abstract

The aim of this investigation was to study the influence of genetic polymorphisms of biotransformation enzymes and dopamine receptors on neurobehavioral effects in referents (n = 53), solvent-workers (n = 144), and chronic toxic encephalopathy (CTE) patients (n = 33). All participants were interviewed for exposure data and confounding factors and underwent a clinical examination. Neurobehavioral complaints (neurotoxicity symptom checklist-60) and effects [simple reaction time (SRT), symbol digit substitution (SDS), hand–eye coordination (HEC), and digit span backwards (DSB)] were evaluated with a computer assisted test battery. The following genotypes were determined: GSTM1, GSTT1, GSTP1, DRD2 Taq1A, DRD2 Taq1B, and DRD2-141Cdel. Neurotoxic effects and complaints were significantly higher in CTE patients and were related to both duration and level of exposure. An equal distribution of genotypes was found between all groups. Logistic regression analysis revealed that GSTT1 was negatively associated with sleep and sensorimotor complaints. GSTM1 had a protecting influence on the relationship between logDSB and the cumulative exposure index and between logSRT and cumulative exposure index and degree of exposure, respectively. This effect was also found when correcting for age, education level, alcohol consumption, and smoking. DRD2-141Cdel polymorphisms had a negative influence on the relationship between logSDS and the total exposure time. GSTT1 might be protective against sleep and sensorimotor complaints, whereas GSTM1 seems to decrease sustained attention and short-term memory problems in relation to solvent exposure. Individuals possessing DRD2-141Cdel variant experienced more visuomotor problems.

Keywords

Polymorphism Genetic Neurotoxicity syndromes Toxic encephalopathy Volatile organic compounds Susceptibility Genetic 

Abbreviations

CTE

Chronic toxic encephalopathy

GST

Glutathione S-transferase

CYP P450

Cytochrome P450

EPHX1

Microsomal epoxide hydrolase 1

DRD

Dopamine D receptor

SRT

Simple reaction time

SDS

Symbol digit substitution

HEC

Hand–eye coordination

DSB

Digit span backwards

NSC-60

Neurotoxicity symptom checklist-60

References

  1. Ahmadi A, Jonsson P, Flodin U, Soderkvist P (2002) Interaction between smoking and glutathione S-transferase polymorphisms in solvent-induced chronic toxic encephalopathy. Toxicol Ind Health 18:289–296CrossRefPubMedGoogle Scholar
  2. Arand M, Mühlbauer R, Hengstler J, Jäger E, Fuchs J, Winkler L, Oesch F (1996) A multiplex polymerase chain reaction protocol for the simultaneous analysis of the glutathione S-transferase GSTM1 and GSTT1 polymorphisms. Anal Biochem 236:184–186CrossRefPubMedGoogle Scholar
  3. Arinami T, Gao M, Hamaguchi H, Toru M (1997) A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia. Hum Mol Genet 6:577–582CrossRefPubMedGoogle Scholar
  4. Bellgrove MA, Mattingley JB (2008) Molecular genetics of attention. Ann N Y Acad Sci 1129:200–212CrossRefPubMedGoogle Scholar
  5. Booij J, Tissingh G, Winogrodzka A, van Royen EA (1999) Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with parkinsonism. Eur J Nucl Med 26:171–182CrossRefPubMedGoogle Scholar
  6. Brebels R, Viaene MK (2008) Chronic toxic encephalopathy by solvents: 10 years experience with a difficult diagnosis (in Dutch). Patient Care Neuropsychiatrie 5–9Google Scholar
  7. Bulterys S, Viaene MK (1994) The development of a screening test for the neuropsycho-logical evaluation of solvent-exposed workers [abstract]. Abstract book 5th international symposium on neurobehavioral methods and effects in occupational and environmental health. CairoGoogle Scholar
  8. Connor JP, Young RM, Lawford BR, Ritchie TL, Noble EP (2002) D(2) dopamine receptor (DRD2) polymorphism is associated with severity of alcohol dependence. Eur Psychiatry 17:17–23CrossRefPubMedGoogle Scholar
  9. Dick FD (2006) Solvent neurotoxicity. Occup Environ Med 63:221–226CrossRefPubMedGoogle Scholar
  10. Dick F, Semple S, Osborne A, Soutar A, Seaton A, Cherrie JW, Walker LG, Haites N (2002) Organic solvent exposure, genes, and risk of neuropsychological impairment. QJM 95:379–387CrossRefPubMedGoogle Scholar
  11. Dick FD, De Palma G, Ahmadi A, Osborne A, Scott NW, Prescott GJ, Bennett J, Semple S, Dick S, Mozzoni P, Haites N, Wettinger SB, Mutti A, Otelea M, Seaton A, Soderkvist P, Felice A (2007) Gene-environment interactions in parkinsonism and Parkinson’s disease: the Geoparkinson study. Occup Environ Med 64:673–680CrossRefPubMedGoogle Scholar
  12. Dryson EW, Ogden JA (2000) Organic solvent induced chronic toxic encephalopathy: extent of recovery, and associated factors, following cessation of exposure. Neurotoxicology 21:659–665PubMedGoogle Scholar
  13. Edling C, Hellman B, Arvidson B, Andersson J, Hartvig P, Lilja A, Valind S, Långström B (1997) Do organic solvents induce changes in the dopaminergic system? Positron emission tomography studies of occupationally exposed subjects. Int Arch Occup Environ Health 70:180–186CrossRefPubMedGoogle Scholar
  14. Frank MJ, Hutchison K (2009) Genetic contributions to avoidance-based decisions: striatal D2 receptor polymorphisms. Neuroscience [Epub ahead of print]Google Scholar
  15. Garte S, Zocchetti C, Taioli E (1997) Gene–environment interactions in the application of biomarkers of cancer susceptibility in epidemiology. IARC Sci Publ 25:1–264Google Scholar
  16. Godderis L, De Boeck M, Haufroid V, Emmery M, Mateuca R, Gardinal S, Kirsch-Volders M, Veulemans H, Lison D (2004) Influence of genetic polymorphisms on biomarkers of exposure and genotoxic effects in styrene-exposed workers. Environ Mol Mutagen 44:293–303CrossRefPubMedGoogle Scholar
  17. Godderis L, Braeckman L, Vanhoorne M, Viaene M (2006a) Neurobehavioral and clinical effects in workers exposed to CS(2). Int J Hyg Environ Health 209:139–150CrossRefPubMedGoogle Scholar
  18. Godderis L, Aka P, Mateuca R, Kirsch-Volders M, Lison D, Veulemans H (2006b) Dose-dependent influence of genetic polymorphisms on DNA damage induced by styrene oxide, ethylene oxide and gamma-radiation. Toxicology 219:220–229CrossRefPubMedGoogle Scholar
  19. Golimbet VE, Aksenova MG, Nosikov VV, Orlova VA, Kaleda VG (2003) Analysis of the linkage of the Taq1A and Taq1B loci of the dopamine D2 receptor gene with schizophrenia in patients and their siblings. Neurosci Behav Physiol 33(3):223–225CrossRefPubMedGoogle Scholar
  20. Hageman G, van der Hoek J, van Hout M, van der Laan G, Steur EJ, de Bruin W, Herholz K (1999) Parkinsonism, pyramidal signs, polyneuropathy, and cognitive decline after long-term occupational solvent exposure. J Neurol 246:198–206CrossRefPubMedGoogle Scholar
  21. Haufroid V, Jakubowski M, Janasik B, Ligocka D, Buchet JP, Bergamaschi E, Manini P, Mutti A, Ghittori S, Arand M, Hangen N, Oesch F, Hirvonen A, Lison D (2002) Interest of genotyping and phenotyping of drug-metabolizing enzymes for the interpretation of biological monitoring of exposure to styrene. Pharmacogenetics 12:691–702CrossRefPubMedGoogle Scholar
  22. Hoenicka J, Aragues M, Ponce G, Rodriguez-Jimenez R, Jimenez-Arriero MA, Palomo T (2007) From dopaminergic genes to psychiatric disorders. Neurotox Res 11:61–72CrossRefPubMedGoogle Scholar
  23. Hogstedt C, Hane M, Axelson O (1980) Diagnostic and health care aspects of workers exposed to solvents. In: Zenz C (ed) Developments in occupational medicine. Year Book Medical Publisher Inc., Chicago, London, pp 249–258Google Scholar
  24. Hooisma J, Emmen HH (1992) Development of cut-off scores for the Neurotoxicity Symptom Checklist (NSC-60). Stichting Arbouw, AmsterdamGoogle Scholar
  25. Iregren A, Gamberale F (1990) Human behavioral toxicology. Central nervous effects of low-dose exposure to neurotoxic substances in the work environment. Scand J Work Environ Health 16(suppl 1):17–25PubMedGoogle Scholar
  26. Kanada M, Miyagawa M, Sato M, Hasegawa H, Honma T (1994) Neurochemical profile of effects of 28 neurotoxic chemicals on the central nervous system in rats. Effects of oral administration on brain contents of biogenic amines and metabolites. Ind Health 32:145–164CrossRefPubMedGoogle Scholar
  27. Kezic S, Calkoen F, Wenker MA, Jacobs JJ, Verberk MM (2006) Genetic polymorphism of metabolic enzymes modifies the risk of chronic solvent-induced encephalopathy. Toxicol Ind Health 22:281–289CrossRefPubMedGoogle Scholar
  28. Kirsch-Volders M, Mateuca RA, Roelants M, Tremp A, Zeiger E, Bonassi S, Holland N, Chang WP, Aka PV, Deboeck M, Godderis L, Haufroid V, Ishikawa H, Laffon B, Marcos R, Migliore L, Norppa H, Teixeira JP, Zijno A, Fenech M (2006) The effects of GSTM1 and GSTT1 polymorphisms on micronucleus frequencies in human lymphocytes in vivo. Cancer Epidemiol Biomarkers Prev 15:1038–1042CrossRefPubMedGoogle Scholar
  29. Laffon B, Perez-Cadahia B, Pasaro E, Mendez J (2003) Individual sensitivity to DNA damage induced by styrene in vitro: influence of cytochrome p450, epoxide hydrolase and glutathione S-transferase genotypes. Toxicology 186:131–141CrossRefPubMedGoogle Scholar
  30. Lerman C, Jepson C, Wileyto EP, Epstein LH, Rukstalis M, Patterson F, Kaufmann V, Restine S, Hawk L, Niaura R, Berrettini W (2006) Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials. Neuropsychopharmacology 31:231–242PubMedGoogle Scholar
  31. Letz R (1991) Use of computerized test batteries for quantifying neurobehavioral outcomes. Environ Health Perspect 90:195–198CrossRefPubMedGoogle Scholar
  32. Letz R, DiIorio CK, Shafer PO, Yeager KA, Schomer DL, Henry TR (2003) Further standardization of some NES3 tests. Neurotoxicology 24(4–5):491–501CrossRefPubMedGoogle Scholar
  33. Munafo MR, Matheson IJ, Flint J (2007) Association of the DRD2 gene Taq1A polymorphism and alcoholism: a meta-analysis of case–control studies and evidence of publication bias. Mol Psychiatry 12:454–461PubMedGoogle Scholar
  34. Noble EP (2000) The DRD2 gene in psychiatric and neurological disorders and its phenotypes. Pharmacogenomics 1:309–333CrossRefPubMedGoogle Scholar
  35. Sarmanova J, Tynkova L, Susova S, Gut I, Soucek P (2000) Genetic polymorphisms of biotransformation enzymes: allele frequencies in the population of the Czech Republic. Pharmacogenetics 10:781–788CrossRefPubMedGoogle Scholar
  36. Söderkvist P, Ahmadi A, Akerback A, Axelson O, Flodin U (1996) Glutathione S-transferase M1 null genotype as a risk modifier for solvent-induced chronic toxic encephalopathy. Scand J Work Environ Health 22:360–363PubMedGoogle Scholar
  37. Tan EK, Tan Y, Chai A, Tan C, Shen H, Lum SY, Fook-Cheong SM, Teoh ML, Yih Y, Wong MC, Zhao Y (2003) Dopamine D2 receptor TaqIA and TaqIB polymorphisms in Parkinson’s disease. Mov Disord 18(5):593–595CrossRefPubMedGoogle Scholar
  38. Viaene MK (2002) Overview of the neurotoxic effects in solvent-exposed workers. Arch Public Health 60:217–232Google Scholar
  39. Viaene MK, Roels HA, Leenders J, De Groof M, Swerts LJ, Lison D, Masschelein R (1999) Cadmium: a possible etiological factor in peripheral polyneuropathy. Neurotoxicology 20:7–16PubMedGoogle Scholar
  40. Viaene MK, Roels HA, Leenders J, De Groof M, Swerts LJ, Lison D, Masschelein R (2001) Neurobehavioural changes and persistence of complaints in workers exposed to styrene in a polyester boat building plant: influence of exposure characteristics and microsomal epoxide hydrolase phenotype. Occup Environ Med 58(2):103–112CrossRefPubMedGoogle Scholar
  41. Visser I, Lavini C, Booij J, Reneman L, Majoie C, de Boer AG, Wekking EM, de Joode EA, van der Laan G, van Dijk FJ, Schene AH, Den Heeten GJ (2008) Cerebral impairment in chronic solvent-induced encephalopathy. Ann Neurol 63:572–580CrossRefPubMedGoogle Scholar
  42. White RF, Proctor SP (1997) Solvents and neurotoxicity. Lancet 349:1239–1243CrossRefPubMedGoogle Scholar
  43. World Health Organization and Nordic Council of Ministers Working group (1985) Chronic effects of organic solvents on the central nervous system and diagnostic criteria. Environ Health 5:20–35Google Scholar
  44. Zhang Y, Bertolino A, Fazio L, Blasi G, Rampino A, Romano R, Lee M-LT, Xiao T, Papp A, Wang D, Sadée W (2007) Polymorphisms in human dopamine D2 receptor gene affect gene expression, splicing, and neuronal activity during working memory. Proc Natl Acad Sci USA 104(51):20552–20557CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • L. Godderis
    • 1
    • 2
  • N. Maertens
    • 2
  • V. de Gelder
    • 3
  • A. De Lamper
    • 4
  • K. De Ruyck
    • 3
  • M. Vernimmen
    • 4
  • S. Bulterys
    • 2
  • G. Moens
    • 1
    • 2
  • H. Thierens
    • 3
  • M. K. Viaene
    • 1
    • 5
  1. 1.Faculty of Medicine, Department of Occupational, Environmental and Insurance MedicineKatholieke Universiteit LeuvenLeuvenBelgium
  2. 2.IDEWE, External Service for Prevention and Protection at WorkHeveleeBelgium
  3. 3.Faculty of Medicine, Department of Basic Medical SciencesGhent UniversityGhentBelgium
  4. 4.Johnson & JohnsonBeerseBelgium
  5. 5.Neuropsychotoxicological Expertise Center, Governmental Psychiatric HospitalGeelBelgium

Personalised recommendations